In what could prove to be a major breakthrough for cancer patients, an mRNA-based vaccine has been developed, demonstrating 100% efficacy and safety in clinical trials.

The Enteromix vaccine showed promising results during trials, helping patients with large tumors by significantly reducing their size and effectively destroying cancer cells, reports WION.

According to Russia Today (RT), the vaccine is now only awaiting final approval from the Russian Ministry of Health for public rollout.

Developed in Russia, Enteromix is the first cancer vaccine to utilize the same mRNA technology platform that was successfully used in COVID-19 vaccines.

This next-generation immunotherapy is designed to precisely target and eliminate cancer cells, offering new hope to millions of cancer patients worldwide.

Enteromix is administered via intramuscular injection and has already been introduced for early clinical use in several oncology centers across Russia.

Unlike traditional treatments like chemotherapy or radiation, Enteromix follows a personalized approach, tailoring the therapy to each individual patient.

Notably, no serious side effects were reported during clinical trials.

The vaccine was developed by the Russian Ministry of Health’s National Medical Research Radiological Centre, in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences (RAS).

Who can benefit from Enteromix?

Patients suffering from lung, breast, colorectal, or pancreatic cancers can benefit from the vaccine. It may also be effective for high-risk individuals with hereditary cancer syndromes (e.g., BRCA1/2) and those whose cancers are resistant to chemotherapy.

Additionally, immunocompromised patients who cannot tolerate conventional treatments may look to Enteromix as a safer alternative.

Following its successful clinical trials, the vaccine now only awaits regulatory clearance from the Russian government.